Recent Finacing
Recent Raise
Gradalis manufactures Vigil, an autologous bi‑shRNA–modified cellular immunotherapy produced from patient tumor tissue in a two‑day Dallas process for intradermal dosing every 3–4 weeks and Phase 2 development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at Gradalis.
